Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Trial of TLC399 (ProDex) in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)

NCT02006147 is registered in ClinicalTrials.gov with Taiwan Liposome Company as lead sponsor.

NCT NCT02006147
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02006147 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Trial of TLC399 (ProDex) in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)
Lead sponsor
Taiwan Liposome Company
Phase
Phase 1/2
Overall status
Completed
Start date
November 30, 2014
Completion date
July 15, 2020
Enrollment
14 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

branch retinal vein occlusion with macular edema, central retinal vein occlusion with macular edema